A Phase 2 Prospective, Multicenter, Randomized, Double-masked, Controlled Study to Evaluate the Efficacy and Safety and Dose-response of the Bimatoprost Ocular Insert (2.2mg, 13mg) With and Without Concomitant Artificial Tears Compared to a Placebo Ocular Insert With and Without Concomitant Timolol (0.5%) Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension.

Trial Profile

A Phase 2 Prospective, Multicenter, Randomized, Double-masked, Controlled Study to Evaluate the Efficacy and Safety and Dose-response of the Bimatoprost Ocular Insert (2.2mg, 13mg) With and Without Concomitant Artificial Tears Compared to a Placebo Ocular Insert With and Without Concomitant Timolol (0.5%) Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2016

At a glance

  • Drugs Bimatoprost (Primary) ; Timolol
  • Indications Glaucoma; Ocular hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ForSight VISION5
  • Most Recent Events

    • 17 Nov 2015 Status changed from active, no longer recruiting to completed, according to a ForSight VISION5 media release.
    • 11 Jun 2015 According to a ForSight VISION5 company media release, company expecting top-line data from this trial in second half of 2015.
    • 11 Jun 2015 According to a ForSight VISION5 company media release, study enrolled 121 subjects at ten clinical sites in the USA in under nine weeks.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top